menu
    • menu

    Company profile for TG Therapeutics

    NEW Drugs in Dev: 8
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found ...
    TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily inhibitor of PI3K-delta.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TG TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Gansevoort Street, 9th Floor New York, NY 10014
    Telephone
    Telephone
    212.554.4484
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tgtherapeutics.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/tg-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/tgtherapeutics?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TG Therapeutics Boosts BRIUMVI Revenue Guidance In Q1 2026 Update
    TG Therapeutics Boosts BRIUMVI Revenue Guidance In Q1 2026 Update

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288663/8790/en/tg-therapeutics-reports-first-quarter-2026-financial-results-and-raises-briumvi-revenue-guidance.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    TG Therapeutics To Host Q1 2026 Financial Results Conference Call
    TG Therapeutics To Host Q1 2026 Financial Results Conference Call

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3284732/8790/en/tg-therapeutics-to-host-conference-call-on-first-quarter-2026-financial-results-and-business-update.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    TG Therapeutics Completes Enrollment For BRIUMVI Phase 3 Trial
    TG Therapeutics Completes Enrollment For BRIUMVI Phase 3 Trial

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274330/8790/en/TG-Therapeutics-Announces-Completion-of-Enrollment-for-the-Phase-3-Trial-Evaluating-Subcutaneous-BRIUMVI.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    TG Therapeutics Secures $500M, Expands $300M Buyback
    TG Therapeutics Secures $500M, Expands $300M Buyback

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258881/8790/en/TG-Therapeutics-Secures-an-Additional-500-Million-in-Non-Dilutive-Capital-from-Blue-Owl-and-Expands-Share-Repurchase-Program-to-300-Million.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Briumvi Cuts Relapse And MRI Activity In Active RMS Study
    Briumvi Cuts Relapse And MRI Activity In Active RMS Study

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251730/8790/en/Data-Published-in-Neurology-and-Therapy-Demonstrate-Significant-Reductions-in-Relapse-and-MRI-Activity-with-BRIUMVI-in-People-with-Highly-Active-Relapsing-Multiple-Sclerosis.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    TG Therapeutics Reveals BRIUMVI Data Presentations At AAN 2026
    TG Therapeutics Reveals BRIUMVI Data Presentations At AAN 2026

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3250976/8790/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2026-Annual-Meeting.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search